Fig. 4: Immunotherapy induced structural variations, microtubule defects and chromoplexy in patient 4. | British Journal of Cancer

Fig. 4: Immunotherapy induced structural variations, microtubule defects and chromoplexy in patient 4.

From: Urine-derived bladder cancer organoids (urinoids) as a tool for cancer longitudinal response monitoring and therapy adaptation

Fig. 4

a Patient 4 total structural variation counts of BTOR4.1: tissue-derived tumoroids patient 4 before immunotherapy; BTOR4.2 tissue-derived tumoroids patient 4 post immunotherapy and UBTOR4.2 urinoids post immunotherapy from the GRIDSS-PURPLE-LINX pipeline. b Highest quality scoring SNP enrichment terms (n = 50) of SNPs only found in post-treatment organoids affecting genes associated with GO terms of Cellular Components (CC, left) and Biological Process (BP, right), significance using false discovery rate (P < 0.05), bold italic highlighted terms are associated with microtubules. Complex multichromosomal linked structural variations as found by the LINX analysis of the GRIDSS-PURPLE-LINX pipeline for c tumoroid BTOR4.2 on chromosomes 5, 10, 17, 21 & Y and d urinoid UBTOR4.2 on chromosomes 1, 5, 10, 17, 20, 21 and Y.

Back to article page